HC Wainwright Analysts Cut Earnings Estimates for AnaptysBio

Key Points

• HC Wainwright has reduced its Q3 2025 earnings estimate for AnaptysBio to ($1.59) per share, down from a prior forecast of ($1.51).
• The biotechnology company currently has a "Buy" rating and a price target of $59.00, while the consensus earnings estimate for the full year is (6.08) per share.
• AnaptysBio's shares rose 4.4% on the day, opening at $31.97, with a market capitalization of $895.16 million.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 earnings estimates for AnaptysBio in a research note issued on Tuesday, September 30th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will post earnings per share of ($1.59) for the quarter, down from their prior forecast of ($1.51). HC Wainwright currently has a "Buy" rating and a $59.00 price target on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio's Q4 2025 earnings at ($1.62) EPS, FY2025 earnings at ($5.82) EPS, FY2026 earnings at ($6.35) EPS, FY2027 earnings at ($11.93) EPS, FY2028 earnings at ($3.94) EPS and FY2029 earnings at ($1.88) EPS.

ANAB has been the topic of several other reports. UBS Group reiterated a "neutral" rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Wedbush restated an "outperform" rating and set a $45.00 price objective on shares of AnaptysBio in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $48.75.

AnaptysBio Trading Up 4.4%

Shares of ANAB stock opened at $31.97 on Thursday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $36.54. The firm's fifty day moving average price is $22.25 and its two-hundred day moving average price is $21.63. The firm has a market capitalization of $895.16 million, a P/E ratio of -7.14 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. The firm had revenue of $22.26 million for the quarter, compared to analyst estimates of $11.55 million.

Institutional Trading of AnaptysBio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP raised its position in shares of AnaptysBio by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company's stock valued at $880,000 after buying an additional 528 shares in the last quarter. Rhumbline Advisers increased its position in AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company's stock worth $574,000 after purchasing an additional 826 shares in the last quarter. US Bancorp DE increased its position in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares in the last quarter. Corton Capital Inc. increased its position in AnaptysBio by 12.2% during the 2nd quarter. Corton Capital Inc. now owns 12,004 shares of the biotechnology company's stock worth $266,000 after purchasing an additional 1,305 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in AnaptysBio by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company's stock worth $193,000 after purchasing an additional 1,359 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.